| ||||
NEWS, PUBLICATIONS, AND RELATED STORIES Discovery's Edge - Mayo's Research Publication What causes brain tumors? Using statistics from Mayo’s enormous patient databases, genetics researchers are learning how genetic mutations and environmental triggers increase the risk of developing brain cancer. View Related   Mayo Clinic Cancer Center receives an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center.   In the May 15 issue of Cancer, Mayo researchers showed that the levels of three proteins (survivin, B7-H1, ki-67) in ccRCC tumor tissue can be used to predict which patients will ultimately die from their cancer. View Abstract  Presented at the annual meeting of the American Association for Cancer Research (AACR). View Related    Presented at the annual meeting of the American Society of Hematology (ASH). The study focused on the impact of statin use on outcomes of patients with two most common lymphoma types, diffuse large B-cell lymphoma and follicular lymphoma. Examples of commonly used statins in the U.S. include Lipitor, Zocor, Parvachol, Lescol, Mevacor and Crestor. View Abstract  William C. Rupp, M.D., has been appointed CEO for the Florida campus effective Nov. 21, Mayo Clinic announced today. Rupp currently leads quality projects for Luther Midelfort, part of Mayo Health System, as well as Mayo Clinic.  Brooke Fridley, Ph.D., has joined Mayo Clinic's Comprehensive Cancer Center as a statistical geneticist to enhance pharmacogenomics studies. View Related   The Gail model calculates probabilities that a woman will develop invasive breast cancer during the next five years, and by age 90. "We found that, for the group of women with atypia, the model predicted significantly fewer invasive breast cancers than were actually observed," says Shane Pankratz, Ph.D., Mayo Clinic statistician and a lead investigator in the study. "We also observed that the model was not able to reliably identify the women who were actually at higher risk of developing breast cancer." View Abstract    About 7.4 percent of U.S. women have asthma. The study found that the prevalence of asthma among breast cancer patients with recurrence of their disease as metastases in the lung is two-fold higher than among non-asthmatic women with breast cancer. "If you are a breast cancer patient with asthma, taking your anti-inflammatory inhaled steroids may be more important to you than simply stopping your wheezing" says James Lee, Ph.D., a Mayo Clinic researcher in Arizona and the senior author of the study. View Abstract  Medical Edge Newspaper I have a niece who's 15. Her mother died of inflammatory breast cancer at age 27. Her maternal grandmother died of cancer at age 37. Do you recommend gene testing? Will a positive result affect her insurance coverage? When and how should we start monitoring? View Related  Publication: Cancer Research -- June 15, 2008  Patient Story -- Sharon Francis Sharon Francis was working on a new design collection when the pain started. View Related     The research team discovered that women whose atypia tissue expressed COX-2 enzymes were more likely to develop breast cancer subsequently, and that the more the enzyme expressed, the higher the risk. View Abstract  Patient Story -- Keri Christian After surviving breast cancer, Keri Christian underwent genetic counseling to help safeguard her family's future health. View Related Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related Mayo Clinic Cancer Center IDs two signatures predicting survival The team found two survival-related 50-gene signatures, one for each of the two cancer types. These were nonoverlapping and largely unique in gene content compared to previously identified predictive gene expression signatures for lung cancer developed by other researchers. View Related  Patient Story -- Janet Vittone Janet Vittone, M.D., two sisters and her mother were diagnosed with breast cancer in the same year — and received the same swift treatment at Mayo Clinic. View Related   Presented at the 2007 San Antonio Breast Cancer Symposium "We need to be aware that this kind of cancer is high risk and we should do all that we can to prevent brain metastasis," says Stephanie Hines, M.D. "For women with triple negative breast cancer, improvements in outcome will likely come when new treatments for this type of cancer are successfully developed." View Related Presented - American Society of Hematology's 2007 meeting "We believe this to be the first large systematic evaluation of the risk factors leading to leukemic transformation in primary myelofibrosis," says Jocelyn Huang, M.D., lead author and hematology researcher at Mayo Clinic. "And in the process, we discovered some unexpected results." View Related     Study presented at the American Society of Human Genetics Annual Meeting http://genetics.faseb.org/genetics/ashg/menu-annmeet.shtml View Related  Study presented at the American Society of Human Genetics Annual Meeting http://genetics.faseb.org/genetics/ashg/ashgmenu.htm View Related     The findings may also be relevant to other cancers, such as breast, ovarian, prostate, bladder, lung and colon cancers, in which loss of sFRP-1 function is common. "Through understanding the important role sFRP-1 plays, we may be able to eventually tailor human therapies to restore its function in this type of kidney cancer and in other cancers," explains the study's senior investigator, John A. Copland, Ph.D., a molecular biologist at Mayo Clinic Cancer Center. View Abstract  Until now there were no strongly-predictive molecules for prostate cancer. "This discovery will allow physicians to individualize treatment and observation plans for prostate cancer patients," says Timothy Roth, M.D., a Mayo Clinic urology resident and lead author of the study. "Being able to tell a patient his specific risk after surgery, and perhaps even prior to surgery, will be a huge step forward." View Abstract  Highly effective translational research collaboration continues Mayo Clinic Cancer Center is a national recognition of excellence in education, research and treatment of cancer. The lymphoma SPORE is one of six SPORE cancer research programs at Mayo's locations in Arizona, Florida and Minnesota. Mayo Clinic also has been awarded SPORE grants in brain, breast, pancreatic and prostate cancer, and shares a SPORE for myeloma. View Related    Women with at least three sites of cellular atypia in breast tissue are nearly eight times more likely than average women to develop breast cancer, according to findings of a Mayo Clinic Cancer Center led study of women with atypical hyperplasia. "With the ability to stratify the risk of breast cancer in women with atypia, we can have more informed discussions with our patients regarding their personal risk," says Amy Degnim, M.D., a Mayo Clinic surgeon and study author. "This will help us to have individualized discussions regarding how aggressively to pursue risk-reduction treatments." View Abstract  Mayo Clinic Cancer Center had researchers from many disciplines presenting more than 60 oral abstracts and dozens of posters, also educational sessions and other special events throughout the 2007 ASCO program, June 1-5. View Related  The National Institutes of Health chose Mayo Clinic as one of the first 12 institutions to receive Clinical and Translational Science Awards (CTSA) in October 2006. "There are two objects in medical education: to heal the sick and advance the science." - Dr. Charles H. Mayo   Special Event: May 14-17, 2007 -- Phoenix, Ariz. "Every day, thousands of children and adults with leukemia, lymphoma and other life-threatening diseases are looking for a donor for a marrow or cord blood transplant," says Jay Maningo-Salinas, R.N., manager of the Apheresis Program at Mayo Clinic. "For a chance to survive, these patients need healthy marrow or blood cells to help their bodies make new, healthy blood cells either from a donor within their family or an unrelated donor from the National Marrow Donor Program Registry." View Related       A Mayo Clinic review and analysis of existing lung cancer studies shows that this technology has not yet surpassed the accuracy of conventional methods used to assess survival in lung cancer patients. "Growing evidence suggests that gene-based prediction is not stable and little is known about the prediction power of a gene expression profile as compared to well-known clinical and pathologic predictors," according to Ping Yang, M.D., Ph.D. View Abstract  Custom-fitting a Drug for a Child with Leukemia Some 20 years ago, Mayo Clinic researcher Richard Weinshilboum, M.D., and colleagues made a groundbreaking discovery: They determined why a dose of a drug that could produce astonishing cures in a lethal childhood cancer sometimes also could produce side effects that killed children. The reason behind this strikingly individual response to a drug was found in the genes. With this profound insight into the role that a patient's genetic make-up plays in how the patient responds to a drug, the new field of pharmacogenomic medicine was born. It continues to grow today—Mayo Clinic research leading the way discovering new treatment applications that range from depression, to breast cancer, to chemical dependency. View Related  Normal aging of breast tissue lessens breast cancer risk, reports a new study by Mayo Clinic Cancer Center researchers published in the Nov. 15, 2006, issue of the Journal of the National Cancer Institute. View Abstract  Mayo Clinic Cancer Center's Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) for prostate cancer research has been renewed for an additional five years. SPORE grants are highly competitive awards given to institutions on the cutting edge of translational research in specific types of cancer. View Related  Medical Edge Television There is a type of breast cancer that often doesn't show up on mammograms. It's called inflammatory breast cancer. IBC can be stopped if you know the signs and symptoms. Read Script   This annual education event brings cutting-edge research and the clinicians and scientists who study it to those who are interested in women's cancers. View Related Mayo Awarded $72 Million for Clinical and Translational Research "The Mayo Clinic Center for Clinical and Translational Research will coordinate the efforts of our outstanding clinical research education and training programs, our world-class scientists and clinical research investigators, and the vast resources of Mayo Clinic to speed the process of turning our research discoveries into the medications and treatments our patients need and expect," says Robert Rizza, M.D., Mayo Clinic's director for research and the director of the new center. View Related  The Clinical Research Training Program provides a formal education in all aspects of clinical research, including grant-writing, legal and ethical issues, statistics, epidemiology and study design and protocols. "I realized how exciting research can be, and how exciting it is to advance the science." Jon Ebbert, M.D. View Related  "These findings reopen the debate about preventive removal of the ovaries for younger women," says Bobbie Gostout, M.D., Mayo Clinic gynecologic surgeon. Death rates rise when women under 45 years old undergo bilateral ovariectomy -- surgical removal of both ovaries -- and do not receive proper hormone replacement therapy, according to a new Mayo Clinic study to be published in the October 1, 2006, issue of The Lancet Oncology. View Abstract  "This collaboration will enable us to work with the Indian Health Service to address health care-related needs specific to Native Americans, ranging from developing research initiatives to address unique problems, to finding ways to improve access to medi View Related  Medical Edge Television One in eight. Those are the odds that your mom, sister, wife or friend has of getting breast cancer in her lifetime. The risk goes way up if you have one of two known breast cancer genes. Read Script In helping young investigators, Mayo Clinic again is connecting all the dots -- leading back to the same point, the same mission, ongoing and yet unchanged for over a century: the needs of the patient come first. New, young investigators are critical to biomedical research. Their fresh ideas, innovativeness, and enthusiasm are necessary for scientific progress. Yet the steps from a junior research position toward a self-sufficient laboratory can be difficult. Mayo Clinic is dedicated to fostering future, investigators. Here we look at two of them and what Mayo is doing to help. View Related  Robert B. Diasio, M.D., has been appointed Mayo Clinic Cancer Center Director, succeeding Franklyn Prendergast, M.D., Ph.D. Dr. Diasio, who will be based at Mayo Clinic in Rochester, will also direct cancer center activities at Mayo Clinic in Arizona and Mayo Clinic in Jacksonville, Fla. View Related  "Once Barrett's esophagus is diagnosed, patients have a 30- to 125-fold increased risk of developing esophageal cancer." View Related The first radiation therapy and respiratory care baccalaureate classes of Mayo School of Health Sciences and the University of Minnesota will be conferred on Friday, May 12, 2006, at Mayo Clinic. View Related  Risk is especially increased if a woman has her ovaries removed at a young age. "Like any medical or surgical decision, there is a trade between risk and benefit," says Dr. Rocca. "Our findings are important for situations where the removal of the ovaries is elective -- that is, conducted to reduce the risk of ovarian cancer." View Related  The 2-gene expression profile of HOXB13 and IL17BR in a woman's breast cancer predicts risk of recurrence in node-negative patients treated with tamoxifen Mayo Clinic researchers report that the expression of two novel genes within the tumors of women with early stage breast cancer may allow identification of women who are and are not at risk for early relapse or cancer-related death. Results of the study are published in the April 1, 2006, issue of Clinical Cancer Research. View Abstract  Researchers have determined that the occurrence rate for monoclonal gammopathy of undetermined significance (MGUS) -- a known precursor condition for multiple myeloma and other related blood disorders -- is nearly twice as high as what has been reported. Mayo Clinic's study results are available in The New England Journal of Medicine. View Abstract  Renal cell carcinoma is one of most dangerous forms of kidney cancer. An interdisciplinary team of Mayo Clinic investigators and Mayo's Comprehensive Cancer Center are pursuing improved treatments by pooling data and expertise with support from Florida. "With this approach, we can halt the disease and begin to cure kidney cancer." John Copland, M.D. View Related In terms of a medical diagnosis, nothing is more devastating than hearing the "C" word - cancer. But now, ASU and Mayo Clinic are hoping that five different C's will become the best arsenal against the big C. The organizations have teamed up to introduce a new research entity called MAC5. MAC5 is short for the Mayo Clinic - ASU Center for Cancer-related Convergence, Cooperation and Collaboration. View Related  City of Rochester employees have a chance to participate in one of the first efforts in the state to further the goals of the Minnesota Cancer Plan, published in 2005. "Colorectal cancer is preventable if people get screened and have appropriate follow-up," says Paul Limburg, M.D., M.P.H., Mayo Clinic gastroenterologist and lead investigator of the study. "We hope to build an education and prevention model here in Rochester that will be useful for communities throughout the state and beyond." View Related  Mayo Clinic Cancer Center researchers report aggressive surgical removal of as much cancer as possible throughout the abdomen in ovarian cancer patients is the best option for most women. Results of the study are published in the January 2006 issue of Obstetrics & Gynecology. View Abstract  Medical Edge Television Ten years ago, 48,000 women -- mothers, wives, sisters -- died every year from breast cancer. Today, that number has dropped to 40,000. But it's still too high. That's why many women who are at high risk of getting breast cancer choose genetic testing. Read Script  Publication: Journal of Clinical Oncology -- Dec. 20, 2005 Results of a pooled analysis from the North Central Cancer Treatment Group View Related       Publication: Journal of Clinical Oncology -- May 15, 2004 North Central Cancer Treatment Group pooled results with US Gastrointestinal Intergroup and the National Surgical Adjuvant Breast and Bowel Project View Related   |
Legal restrictions and terms of use applicable to this site
Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.